Author Archives | SandraKitchen
SandraKitchen - who has written 21 posts on FavStocks.
Sandra has been avidly involved in watching the stock market and writing about the stock movements that interest investors. She specializes in small and mid-cap Biotech stocks with a main focus on public companies awaiting FDA approval of new drugs and/or products.
living in New York, with her family and pets, she stays up on the latest news from the New York Stock Exchange and the FDA. Her goal is to bring the news to investors from a fresh, unbiased, pure research point of view.
AVI BioPharma’s Expansion Plans (NASDAQ:AVII)
AVI BioPharma have recently announced that they have received a funding for expansion plans of their Junin virus drug treatment. Soon after the annoucement was made, AVI BioPharma stocks were trading higher on a surge in volume. AVI BioPharma has announced that they have received expanded contract of approximately US$ 11.5 million from the Defense [...]
Continue reading...Bionovo’s New Offering (NASDAQ:BNVI)
5 October 2009
Comments Off
Bionovo Inc that have always focused on developing treatments for women’s health and breast cancer announced that they might raise around US$ 20 million in gross proceeds from an offering of up to 3.2 million units priced at $6.20 per unit. Each unit consists of ten shares of common stock and ten warrants and each [...]
Continue reading...Catalyst shares on rise (NASDAQ:CPRX)
2 October 2009
Comments Off
October 1st 2009 brought good news to Catalyst Pharmaceutical Partners when they decided to continue with the development of their addiction drug. It was announced that even though they had failed earlier they will still continue with the clinical development of their drug and as soon as the news was out, shares of Catalyst Pharmaceutical [...]
Continue reading...Chelsea Therapeutics Rallies on Droxidopa Data (NASDAQ:CHTP)
1 October 2009
Comments Off
Chelsea Therapeutics International (NASDAQ:CHTP) said its drug Droxidopa has a benefit for five neurological disorder symptoms. CHTP will continue to further investigate these benefits even though last week Chelsea announced the drug did not meet its primary endpoints of the trial. Blame this failure to meet the primary endpoints on a poor trial design and the [...]
Continue reading...Hemispherx’s Vaccine Enhancer Making Waves in Japan (AMEX:HEB)
29 September 2009
Comments Off
Hemispherx Biopharma, Inc. (AMEX:HEB) is in the news after it was announced that Dr. Hasegawa the director of the Japanese National Institute of Infectious Diseases presented data on the lead compounds of Ampligen (R) (Poly I : Poly C12U) the double stranded RNA. The paper was titled “Formulations and Efficacy of the Influenza Vaccine Administered [...]
Continue reading...BioElectronics Making BIG News This Week (BIEL)
15 September 2009
Comments Off
The BioElectronics Corp (Public, OTC BIEL) has been making news this week, with the announcement of their schedule for filing with the U.S. Food and Drug Administration for 510 (K) pre-marketing clearance. It has also been announced the biotech company is a runner up in the 2009 Technology Innovation winners for their wearable drug-free patch [...]
Continue reading...ALR Technologies Patent Approved for Nebulizer Compressors (OTC:ALRT)
15 September 2009
Comments Off
The nebulizer compressors that ALR Technologies (Public, OTC: ALRT) had applied for a patent application has been approved by the U.S. Patent Office. This is a patent to protect the Health-E-Connect management communications system. The Health-E-Connect system will help to remotely monitor patients suffering from chronic asthma, COPD and cystic fibrosis using nebulizer compressors.
Continue reading...Eye Drops Win Unanimous FDA Approval (Nasdaq: ISTA)
11 September 2009
Comments Off
The pharmaceutical company ISTA Pharmaceuticals (Nasdaq: ISTA) won unanimousous support for the approval of their new drug for the treatment of itchy eyes name Bepreve eye drops. The eye drops are designed to treat patients with itchy eyes due to allergies and is for patients ages 2 years and up.  The company’s shares showed the [...]
Continue reading...Clolar Gets Cool Reception From FDA and up for Approval (GENZ, VION)
1 September 2009
Comments Off
Genzyme Corporation (Nasdaq:GENZ) has a new drug application for their new drug Clofarabine ( Clolar), a leukemia drug that will be used to treat older patients. The Food and Drug Administration criticized the biotech company’s clinical study for Clolar, stating the company failed to perform a randomized controlled study to support their application of the [...]
Continue reading...Endo Pharmaceuticals Partners Pending FDA decision (ENDP, LON:PSK)
1 September 2009
Comments Off
Endo Pharmaceuticals (NASDAQ: ENDP) has announced they have partnered up with the U.K. based corporation ProStrakan Group plc (LSE: PSK). The agreement includes the right to commercialize in America, FORTESTA their testosterone gel that is 2 percent. The testosterone transdermal gel is used in testosterone replacement therapy and stays in the categories of the other [...]
Continue reading...
6 October 2009
Comments Off